查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
美國的前列腺癌檢驗市場 (2022-2030年):各生物標記類型、用途、終端用戶、地區的分析、預測
市場調查報告書
商品編碼
1180157

美國的前列腺癌檢驗市場 (2022-2030年):各生物標記類型、用途、終端用戶、地區的分析、預測

U.S. Prostate Cancer Testing Market - A Country Analysis: Focus on Type of Biomarker, Application, End User, and Region - Analysis and Forecast, 2022-2030
出版日期: | 出版商: BIS Research | 英文 197 Pages | 商品交期: 1-5個工作天內

價格

美國的前列腺癌檢驗的市場規模，從2021年的5億4,410萬美元，預計2030年達到19億160萬美元的規模，年複合成長率為14.7％。

對癌症研究領域的高投資和美國的前列腺癌的盛行率上升，預計帶來該市場的成長。

本報告提供美國的前列腺癌檢驗的市場調查，市場概要，市場成長的各種影響因素分析，法律制度，專利趨勢，市場規模的變化、預測，各種區分、各地區的明細，競爭環境，主要企業簡介等彙整資訊。

目錄

第1章 市場

  • 產品定義
  • 市場範圍
  • 調查手法
  • 市場概況
    • 市場定義
    • 市場規模、成長可能性
    • 未來的可能性
    • 前列腺癌檢驗的演進
    • 美國的前列腺癌的流行病學
    • COVID-19對美國的前列腺癌檢驗市場的影響

第2章 產業分析

  • 概要
  • 美國的法律必要條件和架構
  • 專利分析
  • 前列腺癌管理上生物標記所扮演的角色 (美國的PCa的治療指南)

第3章 美國的前列腺癌檢驗市場:市場動態

  • 概要
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會

第4章 美國的前列腺癌檢驗市場:競爭情形

  • 概要
  • 企業策略
  • 事業策略
  • 美國的報銷問題情境
  • 市場佔有率分析 (各企業)

第5章 美國的前列腺癌檢驗市場 (各生物標記類型)

  • 概要
    • 初期評估:攝護腺特異性抗原 (整體PSA、脫離PSA)
    • 切片檢查前/切片檢查陰性後檢驗
    • 切片檢查後的組織檢驗

第6章 美國的前列腺癌檢驗市場 (各用途)

  • 概要
  • 診斷生物標記 (PHI，4KScore，SelectMDx等)
  • 預後生物標記 (Prolaris，OncotypeDx，Decipher等)

第7章 美國的前列腺癌檢驗市場 (各終端用戶)

  • 概要
  • 癌症調查研究機關
  • 診斷實驗室
  • 醫院、診療所
  • 門診病人手術中心 (ASC)
  • 其他

第8章 美國的前列腺癌檢驗市場 (各地區)

  • 概要
  • 美國東北部
  • 美國中西部
  • 美國南部
  • 美國西部

第9章 企業簡介

  • Abbott.
  • Abcam plc.
  • Agilent Technologies, Inc.
  • Bio-Techne. (ExoDx)
  • Cleveland Diagnostics, Inc.
  • Danaher. (Beckman Coulter, Inc.)
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.)
  • H.U. Group Holdings, Inc. (Fujeribio)
  • mdxhealth.
  • Siemens Healthcare GmbH
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories.
  • OPKO Health, Inc. (GenPath)
  • Veracyte, Inc.
Product Code: BHP1297SA

“U.S. Prostate Cancer Testing Market to Reach $1,901.6 Million by 2030.”

U.S. Prostate Cancer Testing Market Industry Overview

The U.S. prostate cancer testing market is anticipated to reach $1,901.6 million in 2030 from $544.1 million in 2021, with a CAGR of 14.7%, during the forecast period 2022-2030. The growth in the U.S. prostate cancer testing market is expected to be driven by high investments in the field of cancer research and the rising prevalence of prostate cancer in U.S. In addition, the focus of business leaders is establishing a deep understanding to address the unmet needs in clinical research to understand the prostate cancer market.

Market Lifecycle Stage

The U.S. prostate cancer testing market is in progressing phase. PSA screening or testing in a general population has increased the incidence of prostate cancer in recent decades. In addition, prostate cancer testing is essential in precision medicine because it assures the safe and successful use of tailored therapies. The majority of the companies in the U.S. prostate cancer testing market provide biomarker tests that are urine, blood, and tissue-based, as well as testing services. Furthermore, applications of prostate cancer testing are primarily clinical and research.

Impact

One of the main reasons for the expansion of the prostate cancer testing market in the upcoming years is the rise in prostate cancer cases. Prostate cancer is the second most frequent disease diagnosed in men, and its frequency is rising across the globe. Prostate cancer is thought to be diagnosed in one million additional cases worldwide each year. Due to an aging population, growing urbanization, and accompanying lifestyle changes, the overall incidence of prostate cancer has increased over the past few decades.

Impact of COVID-19

During the coronavirus disease 2019 (COVID-19) pandemic, a number of disease models issued warnings about an excess of cancer fatalities brought on by missed cancer screenings as a result of the general population's quarantine and a lack of healthcare resources. The COVID-19 pandemic has had a negative impact on early diagnosis in the specific case of prostate cancer, the second most common cancer in men, by reducing participation in screening programs and on time from diagnostic testing to surgery/radiotherapy, which may translate into a worse prostate-cancer-specific death rate in the coming years. Additionally, in other areas, including Florida, state governments disallowed non-essential healthcare services.

Significant reductions in cancer screenings were seen in the early stages of the COVID-19 pandemic. According to a research paper published in January 2022 by the University of Florida, screenings for prostate cancer were reduced by 74%. Due to these screening figures, there may have been thousands more cancer deaths in the U.S. than were registered.

For instance, prostate-specific antigen (PSA) testing rates and the identification of several urological malignancies, including prostate cancer, have been found to be declining in significantly afflicted populations. Several Australian urologists worry that men with possibly curable prostate cancer may have missed their chance for a cure due to low screening test uptake during the lockdowns of 2020. According to a research paper published by BMC Urology in June 2022, a total of 4,048,099 PSA tests and 118,328 prostate biopsies were performed in Australia over the six years of data analysis. In the years 2019 and 2020, 68,429 prostate magnetic resonance imaging (MRI) were performed. Between 2015 and 2019, there were, on average, 19,573 prostate biopsies and 678,082 PSA testing performed per year.

Market Segmentation:

Segmentation 1: by Biomarker Type

  • Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)
  • Pre-Biopsy/Post-Negative Biopsy Testing
  • Post-Biopsy Tissue Testing

Based on biomarker type, the pre-biopsy test in the U.S. prostate cancer testing market is expected to be dominated by the biomarker type segment. This is due to the increasing popularity of prostate cancer testing and rising awareness related to prostate cancer testing.

Segmentation 2: by Application

  • Diagnostics Biomarkers
  • Prognostics Biomarkers

Based on application, the U.S. prostate cancer testing market is dominated by the diagnostics biomarkers segment owing to the rising R&D activity focused on the development of prostate cancer testing. The diagnosis of prostate cancer has developed a new molecular-based diagnostics technology. To detect clinically relevant cancer upon diagnosis, several tools or therapeutic options are required to improve the patient's quality of life.

Segmentation 3: by End User

  • Cancer Research Institutes
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Ambulatory Surgical Center (ASCs)
  • Others

As of 2021, the U.S. prostate cancer testing market (by end user) was dominated by ambulatory surgical centers (ASCs), holding a 28.55% market share with a market value of $155.3 million.

Segmentation 4: by Region

  • Northeast U.S.
  • Midwest U.S
  • South U.S.
  • West U.S.

The TAM of the pre-biopsy/post-negative biopsy testing segment is expected to grow at a CAGR of 4.5% during the forecast period 2022-2030 in the South U.S. prostate cancer testing market. Several established diagnostics manufacturers in this region who are focusing on expanding their portfolios in prostate cancer testing and are collaborating with service providers and pharmaceutical giants to co-market prostate cancer testing solutions with its complementary precision medicine solutions. Moreover, the U.S. government is currently undertaking several initiatives to develop tests for cancer and provide funds to new start-ups in the cancer diagnostics field.

Recent Developments in the U.S. Prostate Cancer Testing Market

  • In September 2022, Veracyte, Inc. announced the publishing of data in the Journal of the National Cancer Institute to demonstrate the company's decipher prostate genomic classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.
  • In August 2019, BioReference Laboratories, Inc. announced the selection by The IPA Association of America (TIPAAA) as its provider of laboratory services and to assist with data analytics for its members' patients. The agreement is designed to enhance patient care and offers collaborative health management tools to TIPAAA members, which includes more than 667 medical organizations in 39 states. The members can have convenient access to BioReference's comprehensive laboratory testing menu, including routine and specialty tests, as well as the 4Kscore for detecting aggressive prostate cancer.
  • In June 2021, Thermo Fisher Scientific announced submissions open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. The grant aims to provide funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients.

Demand - Drivers and Limitations

The following are the demand drivers for the U.S. prostate cancer testing market:

  • Rising Prevalence of Prostate Cancer in the U.S.
  • Increasing Number of Prostate Cancer Screening and Testing
  • Government Initiatives Related to Prostate Cancer

The market is expected to face some limitations due to the following challenges:

  • High Probability of False Positives during Prostate Cancer Testing
  • Clinical Gaps Related to Prostate Cancer Testing

How can this report add value to an organization?

  • Workflow/Innovation Strategy: The workflow segment helps the reader understand the two prostate cancer testing, i.e., initial evaluation: prostate-specific antigen (total PSA, free PSA), pre-biopsy/post-negative biopsy testing, post-biopsy tissue testing, which further aid in diagnosis. Moreover, the study provides the reader with a detailed understanding of the different applications of prostate cancer testing in clinical and research applications.
  • Growth/Marketing Strategy: Prostate cancer testing is being used for both research and clinical application. Various companies are providing urine and blood, and tissue-based biomarkers that aid in the diagnosis, which is also the key strategy for market players to excel in the current prostate cancer testing market.
  • Competitive Strategy: Key players in the U.S. prostate cancer testing market are analyzed and profiled in the study, including manufacturers who are involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the U.S. prostate cancer testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Key Companies Profiled:

  • Abbott.
  • Abcam plc.
  • Agilent Technologies, Inc.
  • Bio-Techne. (ExoDx)
  • Cleveland Diagnostics, Inc.
  • Danaher. (Beckman Coulter, Inc.)
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.)
  • H.U. Group Holdings, Inc. (Fujeribio)
  • mdxhealth.
  • Siemens Healthcare GmbH
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories.
  • OPKO Health, Inc. (GenPath)
  • Veracyte, Inc.

Table of Contents

1 Markets

  • 1.1 Product Definition
    • 1.1.1 Inclusion and Exclusion Criteria
  • 1.2 Market Scope
    • 1.2.1 Scope of the Study
    • 1.2.2 Key Questions Answered in the Report
  • 1.3 Research Methodology
    • 1.3.1 U.S. Prostate Cancer Testing Market: Research Methodology
    • 1.3.2 Data Sources
      • 1.3.2.1 Primary Data Sources
      • 1.3.2.2 Secondary Data Sources
    • 1.3.3 Market Estimation Model
    • 1.3.4 Criteria for Company Profiling
  • 1.4 Market: Overview
    • 1.4.1 Market Definition
    • 1.4.2 Market Footprint and Growth Potential
    • 1.4.3 Future Potential
    • 1.4.4 Evolution of Prostate Cancer Testing
    • 1.4.5 Epidemiology of Prostate Cancer in the U.S.
      • 1.4.5.1 Southern U.S.
      • 1.4.5.2 Midwest U.S.
      • 1.4.5.3 Mid-Atlantic U.S.
      • 1.4.5.4 West U.S.
      • 1.4.5.5 Southwest U.S.
      • 1.4.5.6 New England
    • 1.4.6 COVID-19 Impact on U.S. Prostate Cancer Testing Market
      • 1.4.6.1 COVID-19 Impact on Cancer Care in the U.S.
      • 1.4.6.2 COVID-19 Impact on Prostate Cancer in the U.S.

2 Industry Analysis

  • 2.1 Overview
  • 2.2 Legal Requirements and Framework in the U.S.
    • 2.2.1 National Comprehensive Cancer Network (NCCN) Guidelines
    • 2.2.2 American Urological Association (AUA)
    • 2.2.3 American Cancer Society (ACS)
    • 2.2.4 U.S. Preventive Services Task Force (USPSTF)
  • 2.3 Patent Analysis
    • 2.3.1 Patent Filing Trend
      • 2.3.1.1 Patent Analysis (by Year)
  • 2.4 Role of Biomarkers In Prostate Cancer Management (Guidelines for treatment of PCa in the U.S)

3 U.S. Prostate Cancer Testing Market: Market Dynamics

  • 3.1 Overview
    • 3.1.1 Impact Analysis
  • 3.2 Market Drivers
    • 3.2.1 Rising Prevalence of Prostate Cancer in the U.S.
    • 3.2.2 Increasing Number of Prostate Cancer Screening and Testing
    • 3.2.3 Government Initiatives Related to Prostate Cancer
  • 3.3 Market Restraints
    • 3.3.1 High Probability of False Positives during Prostate Cancer Testing
    • 3.3.2 Clinical Gaps Related to Prostate Cancer Testing
  • 3.4 Market Opportunities
    • 3.4.1 New Treatment Therapy and Technique for Prostate Cancer

4 U.S. Prostate Cancer Testing Market: Competitive Landscape

  • 4.1 Overview
  • 4.2 Corporate Strategies
    • 4.2.1 Mergers and Acquisitions
    • 4.2.2 Synergistic Activities
    • 4.2.3 Business Expansions and Funding
  • 4.3 Business Strategies
    • 4.3.1 Product Launches and Approvals
    • 4.3.2 Regulatory and Legal Activities
    • 4.3.3 Licenses and Agreements
    • 4.3.4 Other Activities
  • 4.4 Reimbursement Scenario in the U.S.
    • 4.4.1 State Efforts to Ensure Prostate Cancer Screening Coverage
    • 4.4.2 Medicare Coverage for Prostate Cancer Screening
    • 4.4.3 Biomarker Testing Reimbursement Scenario in the U.S.
  • 4.5 Market Share Analysis (by Company)

5 U.S. Prostate Cancer Testing Market (by Biomarker Type), Value ($Million), 2021-2030

  • 5.1 Overview
    • 5.1.1 Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)
    • 5.1.2 Pre-Biopsy/Post-Negative Biopsy Testing
      • 5.1.2.1 Blood-Based Biomarker
      • 5.1.2.2 Urine-Based Biomarker
      • 5.1.2.3 Imaging
        • 5.1.2.3.1 Multiparametric Magnetic Resonance Imaging (mp-MRI)
    • 5.1.3 Post-Biopsy Tissue Testing
      • 5.1.3.1 Tissue-Based Biomarker

6 U.S. Prostate Cancer Testing Market (by Application), Value ($Million), 2021-2030

  • 6.1 Overview
  • 6.2 Diagnostic Biomarkers (PHI, 4KScore, SelectMDx, etc.)
  • 6.3 Prognostic Biomarkers (Prolaris, OncotypeDx, Decipher, etc.)

7 U.S. Prostate Cancer Testing Market (by End User), Value ($Million), 2021-2030

  • 7.1 Overview
  • 7.2 Cancer Research Institutes
  • 7.3 Diagnostic Laboratories
  • 7.4 Hospitals and Clinics
  • 7.5 Ambulatory Surgical Centers (ASCs)
  • 7.6 Others

8 U.S. Prostate Cancer Testing Market (by Region), Value ($Million), 2021-2030

  • 8.1 Overview
  • 8.2 Northeast U.S.
    • 8.2.1 Northeast U.S. (Prostate-Specific Antigen (PSA))
    • 8.2.2 Northeast U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 8.2.3 Northeast U.S. (Post-Biopsy Tissue Testing)
  • 8.3 Midwest U.S.
    • 8.3.1 Midwest U.S. (Prostate-Specific Antigen (PSA))
    • 8.3.2 Midwest U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 8.3.3 Midwest U.S. (Post-Biopsy Tissue Testing)
  • 8.4 South U.S.
    • 8.4.1 South U.S. (Prostate-Specific Antigen (PSA))
    • 8.4.2 South U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 8.4.3 South U.S. (Post-Biopsy Tissue Testing)
  • 8.5 West U.S.
    • 8.5.1 West U.S. (Prostate-Specific Antigen (PSA))
    • 8.5.2 West U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 8.5.3 West U.S. (Post-Biopsy Tissue Testing)

9 Company Profiles

  • 9.1 Abbott.
    • 9.1.1 Company Overview
    • 9.1.2 Role of Abbott. in the U.S. Prostate Cancer Testing Market
    • 9.1.3 Key Competitors of the Company
    • 9.1.4 Financials
    • 9.1.5 Key Insights about the Financial Health of the Company
    • 9.1.6 Analyst Perspective
  • 9.2 Abcam plc.
    • 9.2.1 Company Overview
    • 9.2.2 Role of Abcam plc. in the U.S. Prostate Cancer Testing Market
    • 9.2.3 Key Customers of the Company
    • 9.2.4 Key Competitors of the Company
    • 9.2.5 Financials
    • 9.2.6 Analyst Perspective
  • 9.3 Agilent Technologies, Inc.
    • 9.3.1 Company Overview
    • 9.3.2 Role of Agilent Technologies, Inc. in the U.S. Prostate Cancer Testing Market
    • 9.3.3 Key Competitors of the Company
    • 9.3.4 Financials
    • 9.3.5 Analyst Perspective
  • 9.4 Bio-Techne. (ExoDx)
    • 9.4.1 Company Overview
    • 9.4.2 Role of Bio-Techne. (ExoDx) in the U.S. Prostate Cancer Testing Market
    • 9.4.3 Key Competitors of the Company
    • 9.4.4 Financials
    • 9.4.5 Key Insights about the Financial Health of the Company
    • 9.4.6 Corporate Strategies
    • 9.4.7 Business Strategies
    • 9.4.8 Analyst Perspective
  • 9.5 Cleveland Diagnostics, Inc.
    • 9.5.1 Company Overview
    • 9.5.2 Role of Cleveland Diagnostics, Inc. in the U.S. Prostate Cancer Testing Market
    • 9.5.3 Key Competitors of the Company
    • 9.5.4 Corporate Strategies
    • 9.5.5 Business Strategies
    • 9.5.6 Analyst Perspective
  • 9.6 Danaher. (Beckman Coulter, Inc.)
    • 9.6.1 Company Overview
    • 9.6.2 Role of Danaher. (Beckman Coulter, Inc.) in the U.S. Prostate Cancer Testing Market
    • 9.6.3 Key Competitors of the Company
    • 9.6.4 Financials
    • 9.6.5 Key Insights about the Financial Health of the Company
    • 9.6.6 Analyst Perspective
  • 9.7 Exact Sciences Corporation
    • 9.7.1 Company Overview
    • 9.7.2 Role of Exact Sciences Corporation in the U.S. Prostate Cancer Testing Market
    • 9.7.3 Key Customers of the Company
    • 9.7.4 Key Competitors of the Company
    • 9.7.5 Financials
    • 9.7.6 Key Insights about the Financial Health of the Company
    • 9.7.7 Corporate Strategies
    • 9.7.8 Business Strategies
    • 9.7.9 Analyst Perspective
  • 9.8 F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.)
    • 9.8.1 Company Overview
    • 9.8.2 Role of F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.) in the U.S. Prostate Cancer Testing Market
    • 9.8.3 Key Competitors of the Company
    • 9.8.4 Financials
    • 9.8.5 Key Insights about the Financial Health of the Company
    • 9.8.6 Corporate Strategies
    • 9.8.7 Business Strategies
    • 9.8.8 Analyst Perspective
  • 9.9 H.U. Group Holdings, Inc. (Fujeribio)
    • 9.9.1 Company Overview
    • 9.9.2 Role of H.U. Group Holdings, Inc. (Fujeribio) in the U.S. Prostate Cancer Testing Market
    • 9.9.3 Key Competitors of the Company
    • 9.9.4 Financials
    • 9.9.5 Analyst Perspective
  • 9.1 mdxhealth.
    • 9.10.1 Company Overview
    • 9.10.2 Role of mdxhealth. in the U.S. Prostate Cancer Testing Market
    • 9.10.3 Financials
    • 9.10.4 Key Insights about the Financial Health of the Company
    • 9.10.5 Corporate Strategies
      • 9.10.5.1 Mergers and Acquisitions
    • 9.10.6 Business Strategies
    • 9.10.7 Analyst Perspective
  • 9.11 Siemens Healthcare GmbH
    • 9.11.1 Company Overview
    • 9.11.2 Role of Siemens Healthcare GmbH in the U.S. Prostate Cancer Testing Market
    • 9.11.3 Key Competitors of the Company
    • 9.11.4 Financials
    • 9.11.5 Key Insights about the Financial Health of the Company
    • 9.11.6 Analyst Perspective
  • 9.12 Myriad Genetics, Inc.
    • 9.12.1 Company Overview
    • 9.12.2 Role of Myriad Genetics, Inc. in the U.S. Prostate Cancer Testing Market
    • 9.12.3 Key Competitors of the Company
    • 9.12.4 Corporate Strategies
    • 9.12.5 Business Strategies
    • 9.12.6 Financials
    • 9.12.7 Key Insights about the Financial Health of the Company
    • 9.12.8 Analyst Perspective
  • 9.13 NeoGenomics Laboratories.
    • 9.13.1 Company Overview
    • 9.13.2 Role of NeoGenomics Laboratories. in the U.S. Prostate Cancer Testing Market
    • 9.13.3 Key Competitors of the Company
    • 9.13.4 Financials
    • 9.13.5 Key Insights about the Financial Health of the Company
    • 9.13.6 Business Strategies
    • 9.13.7 Analyst Perspective
  • 9.14 OPKO Health, Inc. (GenPath)
    • 9.14.1 Company Overview
    • 9.14.2 Role of OPKO Health, Inc. (GenPath) in the U.S. Prostate Cancer Testing Market
    • 9.14.3 Key Customers of the Company
    • 9.14.4 Key Competitors of the Company
    • 9.14.5 Financials
    • 9.14.6 Key Insights about the Financial Health of the Company
    • 9.14.7 Corporate Strategies
    • 9.14.8 Business Strategies
    • 9.14.9 Analyst Perspective
  • 9.15 Veracyte, Inc.
    • 9.15.1 Company Overview
    • 9.15.2 Role of Veracyte, Inc. in the U.S. Prostate Cancer Testing Market
    • 9.15.3 Key Customers of the Company
    • 9.15.4 Key Competitors of the Company
    • 9.15.5 Financials
    • 9.15.6 Corporate Strategies
    • 9.15.7 Analyst Perspective

List of Figures

  • Figure 1: U.S. Prostate Cancer Testing Market, $Million, 2021 and 2030
  • Figure 2: U.S. Prostate Cancer Testing Market Segmentation
  • Figure 3: Share of U.S. Prostate Cancer Testing Market (by Biomarker Type), Excluding PSA Tests, $Million, 2021 and 2030
  • Figure 4: Share of U.S. Prostate Cancer Testing Market (by Application), $Million, 2021 and 2030
  • Figure 5: Share of U.S. Prostate Cancer Testing Market (by End User), $Million, 2021 and 2030
  • Figure 6: U.S. Prostate Cancer Testing Market Segmentation
  • Figure 7: U.S. Prostate Cancer Testing Market: Research Methodology
  • Figure 8: Primary Research Methodology
  • Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 10: Top-Down Approach (Segment-Wise Analysis)
  • Figure 11: Overview of Prostate Cancer Testing
  • Figure 12: Evolution of Prostate Cancer Testing
  • Figure 13: Percent of Cases by Stage of Prostate Cancer, 2012-2018
  • Figure 14: 5-Year Relative Survival by Stage of Prostate Cancer (2012-2018)
  • Figure 15: Commonality of Prostate Cancer in 2022
  • Figure 16: New Cases (2015-2019) and Death Rates (2016-2020) per 100,000 Persons of Prostate Cancer (by Ethnicity)
  • Figure 17: New Cases (2015-2019) and Death Rates (2016-2020) of Prostate Cancer (by Age Group)
  • Figure 18: Estimated Number of New Prostate Cancer Cases in Southern U.S. (by State), %, 2022
  • Figure 19: Estimated Number of New Prostate Cancer Cases in Midwest U.S. (by State), %, 2022
  • Figure 20: Estimated Number of Prostate Cancer Cases in Mid-Atlantic U.S. (by State), %, 2022
  • Figure 21: Estimated Number of Prostate Cancer Cases in West U.S. (by State), %, 2022
  • Figure 22: Estimated Number of Prostate Cancer Cases in Southwest U.S. (by State), %, 2022
  • Figure 23: Estimated Number of New Prostate Cancer Cases in New England (by State), %, 2022
  • Figure 24: COVID-19 Impact on U.S Prostate Cancer
  • Figure 25: NCCN Guidelines for Prostate Cancer Propose Germline Testing for Patients
  • Figure 26: Year-Wise Analysis of Patents Related to U.S. Prostate Cancer Testing, January 2019-October 2022
  • Figure 27: Role of Biomarkers in Prostate Cancer Management
  • Figure 28: U.S. Prostate Cancer Testing Market - Market Dynamics
  • Figure 29: Likert Scale
  • Figure 30: Impact Analysis of Market Drivers and Market Challenges on the U.S. Prostate Cancer Testing Market
  • Figure 31: Incidence of Prostate Cancer in the U.S. (2015-2020)
  • Figure 32: Share of Key Developments, January 2019-November 2022
  • Figure 33: Share of Mergers and Acquisitions (by Company), January 2019-November 2022
  • Figure 34: Share of Synergistic Activities (by Company), January 2019-November 2022
  • Figure 35: Number of Business Expansions and Funding Activities (by Company), January 2019-November 2022
  • Figure 36: Number of Product Launches and Approvals (by Company), January 2019-November 2022
  • Figure 37: Share of Regulatory and Legal Activities (by Company), January 2019-November 2022
  • Figure 38: Number of Licenses and Agreements (by Company), January 2019-November 2022
  • Figure 39: Number of Other Activities (by Company), January 2019-November 2022
  • Figure 40: Impact on Coverage Expansion ($) of Biomarker Testing on Member Premiums (2022)
  • Figure 41: Market Share Analysis of U.S. Prostate Cancer Testing Market (Pre-Biopsy/Post-Negative Biopsy Testing), 2021
  • Figure 42: Market Share Analysis of U.S. Prostate Cancer Testing Market (Post-Biopsy Tissue Testing), 2021
  • Figure 43: Phases of Biomarker Development
  • Figure 44: Classification of Biomarkers
  • Figure 45: U.S. Prostate Cancer Testing Market (by Biomarker Type)
  • Figure 46: U.S. Prostate Cancer Testing Market for Prostate-Specific Antigen (PSA) (TAM and SAM), $Million, 2021-2030
  • Figure 47: Share of U.S. Prostate Cancer Testing Market (by Biomarker Type), Excluding PSA Tests, $Million, 2021 and 2030
  • Figure 48: U.S. Prostate Cancer Testing Market for Pre-Biopsy/Post-Negative Biopsy Testing (TAM, SAM, and SOM), $Million, 2021-2030
  • Figure 49: U.S. Prostate Cancer Testing Market for Blood-Based Biomarker (SAM), $Million, 2021-2030
  • Figure 50: U.S. Prostate Cancer Testing Market, Urine-Based Biomarker (SAM), $Million, 2021-2032
  • Figure 51: U.S. Prostate Cancer Testing Market, Multiparametric Magnetic Resonance Imaging (mp-MRI) (SAM), $Million, 2021-2030
  • Figure 52: U.S. Prostate Cancer Testing Market for Post-Biopsy Tissue Testing (TAM, SAM, and SOM), $Million, 2021-2030
  • Figure 53: Utility of Tissue-Based Biomarker in Prostate Cancer Management
  • Figure 54: Share of U.S. Prostate Cancer Testing Market (by Application), $Million, 2021 and 2030
  • Figure 55: U.S. Prostate Cancer Testing Market (Diagnostic Biomarker), $Million, 2021-2030
  • Figure 56: U.S. Prostate Cancer Testing Market (Prognostic Biomarker), $Million, 2021-2030
  • Figure 57: U.S. Prostate Cancer Testing Market (by End User)
  • Figure 58: Share of U.S. Prostate Cancer Testing Market (by End User), $Million, 2021 and 2030
  • Figure 59: U.S. Prostate Cancer Testing Market (Cancer Research Institute), $Million, 2021-2030
  • Figure 60: U.S. Prostate Cancer Testing Market (Diagnostic Laboratories), $Million, 2021-2030
  • Figure 61: U.S. Prostate Cancer Testing Market (Hospitals and Clinics), $Million, 2021-2030
  • Figure 62: U.S. Prostate Cancer Testing Market (Ambulatory Surgical Centers), $Million, 2021-2030
  • Figure 63: U.S. Prostate Cancer Testing Market (Others), $Million, 2021-2030
  • Figure 64: New Prostate Cancer Cases in the U.S., 2019
  • Figure 65: Northeast U.S. Prostate Cancer Testing Market (by PSA), $Million, 2021-2030
  • Figure 66: Northeast U.S. Prostate Cancer Testing Market (by Pre-Biopsy/Post-Negative Biopsy Testing), $Million, 2021-2030
  • Figure 67: Northeast U.S. Prostate Cancer Testing Market (by Post-Biopsy Tissue Testing), $Million, 2021-2030
  • Figure 68: Midwest U.S. Prostate Cancer Testing Market (by PSA), $Million, 2021-2030
  • Figure 69: Midwest U.S. Prostate Cancer Testing Market (by Pre-Biopsy/Post-Negative Biopsy Testing), $Million, 2021-2030
  • Figure 70: Midwest U.S. Prostate Cancer Testing Market (by Post-Biopsy Tissue Testing), $Million, 2021-2030
  • Figure 71: South U.S. Prostate Cancer Testing Market (by PSA), $Million, 2021-2030
  • Figure 72: South U.S. Prostate Cancer Testing Market (by Pre-Biopsy/Post-Negative Biopsy Testing), $Million, 2021-2030
  • Figure 73: South U.S. Prostate Cancer Testing Market (by Post-Biopsy Tissue Testing), $Million, 2021-2030
  • Figure 74: West U.S. Prostate Cancer Testing Market (by PSA), $Million, 2021-2030
  • Figure 75: West U.S. Prostate Cancer Testing Market (by Pre-Biopsy/Post-Negative Biopsy Testing), $Million, 2021-2030
  • Figure 76: West U.S. Prostate Cancer Testing Market (by Post-Biopsy Tissue Testing), $Million, 2021-2030
  • Figure 77: Abbott.: Product Portfolio
  • Figure 78: Abbott.: Overall Financials, $Million, 2019-2021
  • Figure 79: Abbott.: Revenue (by Segment), $Million, 2019-2021
  • Figure 80: Abbott.: Revenue (by Region), $Million, 2019-2021
  • Figure 81: Abbott.: R&D Expenditure, $Million, 2019-2021
  • Figure 82: Abcam plc.: Product Portfolio
  • Figure 83: Abcam plc.: Overall Financials, $Million, 2018-2020
  • Figure 84: Abcam plc.: Revenue (by Segment), $Million, 2019-2020
  • Figure 85: Abcam plc.: Revenue (by Region), $Million, 2018-2020
  • Figure 86: Abcam plc.: R&D Expenditure, $Million, 2019-2021
  • Figure 87: Agilent Technologies, Inc.: Product Portfolio
  • Figure 88: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 89: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 90: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 91: Agilent Technologies, Inc: R&D Expenditure, $Million, 2019-2021
  • Figure 92: Bio-Techne. (ExoDx): Product Portfolio
  • Figure 93: Bio-Techne. (ExoDx): Overall Financials, $Million, 2020-2022
  • Figure 94: Bio-Techne. (ExoDx): Revenue (by Segment), $Million, 2020-2022
  • Figure 95: Bio-Techne. (ExoDx): Revenue (by Region), $Million, 2020-2022
  • Figure 96: Bio-Techne. (ExoDx): R&D Expenditure, $Million, 2020-2022
  • Figure 97: Cleveland Diagnostics, Inc.: Product Portfolio
  • Figure 98: Danaher. (Beckman Coulter, Inc.): Product Portfolio
  • Figure 99: Danaher. (Beckman Coulter, Inc.): Overall Financials, $Million, 2019-2021
  • Figure 100: Danaher. (Beckman Coulter, Inc.): Revenue (by Segment), $Million, 2019-2021
  • Figure 101: Danaher. (Beckman Coulter, Inc.): Revenue (by Region), $Million, 2019-2021
  • Figure 102: Danaher. (Beckman Coulter, Inc.): R&D Expenditure, $Million, 2019-2021
  • Figure 103: Exact Sciences Corporation: Product Portfolio
  • Figure 104: Exact Sciences Corporation: Overall Financials, $Million, 2019-2021
  • Figure 105: Exact Sciences Corporation.: Revenue (by Segment), $Million, 2019-2021
  • Figure 106: Exact Sciences Corporation: Revenue (by Region), $Million, 2019-2021
  • Figure 107: Exact Sciences Corporation: R&D Expenditure, $Million, 2019-2021
  • Figure 108: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Product Portfolio
  • Figure 109: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Overall Financials, $Million, 2019-2021
  • Figure 110: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Revenue (by Segment), $Million, 2019-2021
  • Figure 111: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Revenue (by Region), $Million, 2019-2021
  • Figure 112: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): R&D Expenditure, $Million, 2019-2021
  • Figure 113: H.U. Group Holdings, Inc. (Fujeribio): Product Portfolio
  • Figure 114: H.U. Group Holdings, Inc. (Fujeribio): Overall Financials, $Million, 2018-2020
  • Figure 115: H.U. Group Holdings, Inc. (Fujeribio): Revenue (by Segment), $Million, 2019-2021
  • Figure 116: H.U. Group Holdings, Inc. (Fujeribio): R&D Expenditure, $Million, 2018-2020
  • Figure 117: mdxhealth.: Product Portfolio
  • Figure 118: mdxhealth.: Overall Financials, $Million, 2019-2021
  • Figure 119: mdxhealth.: Revenue (by Segment), $Million, 2019-2021
  • Figure 120: mdxhealth.: R&D Expenditure, $Million, 2019-2021
  • Figure 121: Siemens Healthcare GmbH: Product Portfolio
  • Figure 122: Siemens Healthcare GmbH: Overall Financials, $Million, 2019-2021
  • Figure 123: Siemens Healthcare GmbH: Revenue (by Segment), $Million, 2019-2021
  • Figure 124: Siemens Healthcare GmbH: Revenue (by Region), $Million, 2019-2021
  • Figure 125: Siemens Healthcare GmbH: R&D Expenditure, $Million, 2019-2021
  • Figure 126: Myriad Genetics, Inc.: Product Portfolio
  • Figure 127: Myriad Genetics, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 128: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 129: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 130: NeoGenomics Laboratories.: Product Portfolio
  • Figure 131: NeoGenomics Laboratories.: Overall Financials, $Million, 2019-2021
  • Figure 132: NeoGenomics Laboratories.: Revenue (by Segment), $Million, 2019-2021
  • Figure 133: NeoGenomics Laboratories.: R&D Expenditure, $Million, 2019-2021
  • Figure 134: OPKO Health, Inc. (GenPath): Product Portfolio
  • Figure 135: OPKO Health, Inc. (GenPath): Overall Financials, $Million, 2019-2021
  • Figure 136: OPKO Health, Inc. (GenPath): Revenue (by Segment), $Million, 2019-2021
  • Figure 137: OPKO Health, Inc. (GenPath): R&D Expenditure, $Million, 2019-2021
  • Figure 138: Veracyte, Inc.: Product Portfolio
  • Figure 139: Veracyte, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 140: Veracyte, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 141: Veracyte, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 142: Veracyte, Inc: R&D Expenditure, $Million, 2019-2021

List of Tables

  • Table 1: Impact Analysis of Market Drivers, Restraints, and Opportunities on the U.S. Prostate Cancer Testing Market
  • Table 2: Likert Scale
  • Table 3: Numerous Risk Categories for Clinically Localized Prostate Cancer
  • Table 4: Summary of Guidelines for Prostate Cancer Testing
  • Table 5: Recommendations Related to Prostate Cancer Screening
  • Table 6: Screening and Diagnosis Rate in 2019 (by Age Group)
  • Table 7: List of States with Passed Laws for Biomarker Testing Coverage by Health Insurer
  • Table 8: Some of the Emerging Biomarkers Associated with Prostate Cancer and its Clinical Trials
  • Table 9: Prostate-Specific Antigen (PSA) Age Range
  • Table 10: Summary of Prostate-Specific Antigen (PSA) Screening Guidelines
  • Table 11: Blood-Based Biomarkers for Prostate Cancer Testing
  • Table 12: Urine-Based Biomarkers for Prostate Cancer Testing
  • Table 13: Tissue-Based Biomarkers for Prostate Cancer Testing
  • Table 14: Summary of Biomarkers, Clinical Use, and Guidelines
  • Table 15: Estimated Cancer Cases and Deaths due to Prostate Cancer in the U.S. States, 2022